| Literature DB >> 21274275 |
Meghan L Butryn1, Thomas A Wadden, Margaret R Rukstalis, Chanelle Bishop-Gilyard, Melissa S Xanthopoulos, Delroy Louden, Robert I Berkowitz.
Abstract
There is a dearth of research on the long-term efficacy and safety of treatments for adolescent obesity. This narrative review examined several approaches to treatment, focusing on long-term effectiveness data in adolescents, as well as relevant findings from studies of adults. The available research suggests that lifestyle modification has promise in obese adolescents, although it is not clear that any particular dietary or physical activity approach is more effective than another. Meal replacements are quite effective in adults and deserve further research in adolescents. Extending the length of treatment to teach weight loss maintenance skills is likely to improve long-term outcomes in adolescents, and delivering treatment via the Internet or telephone is a novel way of doing so. Treatment that combines lifestyle modification with the medication orlistat generally appears to be safe but only marginally superior to lifestyle modification alone. More research is needed on the management of adolescent obesity, which has been overlooked when compared with research on the treatment of obesity in children and adults.Entities:
Year: 2011 PMID: 21274275 PMCID: PMC3022201 DOI: 10.1155/2010/789280
Source DB: PubMed Journal: J Obes ISSN: 2090-0708
Characteristics of Adolescent Clinical Trials.
| Author | Sample size | Method(s) of data analysis | Attrition at end of study | Length of treatment | Length of followup (i.e., months after treatment completion) |
|---|---|---|---|---|---|
| Mellin et al. [ | 66 | Not clear; presumably completers only | 16% | 3 months | 12 months |
| Jiang et al. [ | 75 | Completers only | 8% | 24 months | None |
| Coates et al. [ | 31 | Not clear; presumably completers only | None reported | 20 weeks | 9 months |
| Brownell et al. [ | 42 | Not clear; presumably completers only | 14% | 16 months (sessions were held every 2 months after the initial 16 weekly sessions) | None |
| Wadden et al. [ | 47 | Completers only | 34% | 4 months | 6 months |
| Coates et al. [ | 42 | ITT, in which return to baseline weight was assumed for participants who did not provide data | 14% | 20 weeks | 6 months |
| Resnicow et al [ | 147 | (1) ITT (unclear how missing data were handled), and (2) inclusion of only those participants who completed at least 75% of treatment sessions | 27% | 6 months | 6 months |
| Ebbeling et al. [ | 16 | ITT, in which return to baseline weight was assumed for participants who did not provide data (completers analysis also reported in paper, with same result) | 13% | 6 months | 6 months |
| Gutin et al. [ | 80 | (1) Completers only and (2) inclusion of only those participants who attended at least 40% of treatment sessions and at least two sessions per week of physical activity | 29% | 8 months | None |
| Jelalian et al. [ | 76 | (1) Completers only and (2) ITT, in which return to baseline weight was assumed for participants who did not provide data | 26% | 4 months | 6 months |
| Williamson et al. [ | 57 | ITT with LOCF (authors also noted that same results were found with completers analyses) | 30% | 24 months | None |
| Doyle et al. [ | 80 | (1) Completers only and (2) ITT, in which return to baseline weight was assumed for participants who did not provide data | 17% | 4 months | 4 months |
| Jones et al. [ | 105 | (1) Completers only and (2) ITT, in which return to baseline weight was assumed for participants who did not provide data | 17% | 4 months | 5 months |
| Chanoine et al. [ | 539 | Modified ITT: inclusion of all randomized participants who completed at least one postbaseline visit, with LOCF for subsequent missing data | 35% | 12 months | None |
| Ozkan et al. [ | 42 | Completers only | 17% | Mean 11.7 ± 3.7 months | None |
Note: ITT : Intention-to-treat analysis; LOCF= last observation carried forward.